FDAnews Drug Daily Bulletin

AKORN SIGNS LETTER OF INTENT WITH AZAD PHARMA AG TO DEVELOP AND SUPPLY THREE ANDA INJECTABLE DRUG PRODUCTS

Dec. 16, 2005
A A

Akorn, Inc. today announced that it has signed a Letter of Intent with Azad Pharma AG, located in Toffen Switzerland, to develop and supply three ANDA injectable drug products for critical care medicine. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Azad.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051214005621&newsLang=en)